Definitive Proxy Filed for Going-Private Merger at $0.066/Share; Shareholder Vote Set for June 19
LSBCF has more than doubled off its 52-week low of $0.028 on elevated volume (2.2× avg).
Summary
LakeShore Biopharma has filed definitive documents for its going-private merger, offering unaffiliated shareholders $0.066 per share, a substantial discount to the current market price, with a shareholder vote scheduled for June 19, 2026.
Key Events · M&A and Partnerships · LSBCF
-
Going-Private Merger Finalized
The company has filed definitive documents for its going-private merger, which will result in it becoming a privately held entity wholly owned by Oceanpine Skyline Inc. and its affiliates.
-
Shareholder Vote Scheduled
An Extraordinary General Meeting (EGM) is scheduled for June 19, 2026, for shareholders to vote on the merger. Approval requires an affirmative vote of at least two-thirds of the votes cast.
-
Offer Price at Significant Discount
Unaffiliated shareholders will receive $0.066 per share in cash, which is approximately 33% below the current market price of $0.0993. This represents a substantial discount to historical trading highs.
-
Arbitral Awards Impact Valuation
The reduced merger consideration is largely due to approximately RMB576.5 million in financial liabilities from arbitral awards, which have materially adverse effects on the company's financial condition and valuation.
Analysis · LSBCF · Life Sciences
LakeShore Biopharma has filed its definitive transaction statement and proxy materials for a going-private merger, with a shareholder vote scheduled for June 19, 2026. Unaffiliated shareholders are offered $0.066 per share in cash, representing a significant discount of approximately 33% to the current stock price of $0.0993. This low offer price is attributed to substantial monetary liabilities from arbitral awards totaling approximately RMB576.5 million, which significantly exceed the company's equity value and are expected to materially impact its financial condition. Rollover shareholders, who collectively own about 53.35% of the voting power, are committed to voting in favor of the merger, making its approval highly probable. The transaction will result in the company's delisting from OTC Pink, removing public liquidity and future upside potential for existing unaffiliated shareholders.
At the time of this filing, LSBCF was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.03 to $2.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.